STOCK TITAN

Nurix CSO sells 1,452 shares after option exercise

After exercising options under a Rule 10b5-1 plan, Hansen still held 60,858 stock options expiring Aug. 28, 2029.

(Neutral)
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Nurix Therapeutics, Inc. (NRIX) reported that Chief Scientific Officer Gwenn Hansen exercised employee stock options for 1,452 shares of common stock at an exercise price of $1.86 per share and on the same date sold 1,452 shares at $25.47 per share. Following the option exercise, Hansen held 60,858 stock options directly, expiring on August 28, 2029. The transactions were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person.

Positive

  • None.

Negative

  • None.
Insider Hansen Gwenn
Role Chief Scientific Officer
Sold 1,452 shs ($37K)
Approx. gross sale proceeds $37K
Approx. exercise cost $3K
Approx. pre-tax spread $34K
Type Security Shares Price Value
Exercise Employee Stock Option (right to buy) F1, F2 1,452 $0.00 $0.00
Exercise Common Stock F1 1,452 $1.86 $3K
Sale Common Stock F1 1,452 $25.47 $37K
Holdings After Transaction: Employee Stock Option (right to buy) — 60,858 contracts (Direct); Common Stock — 117,227 shares (Direct)
Footnotes (2)
  1. F1. This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.
  2. F2. The stock option vested as to 1/48 of the total shares monthly beginning June 10, 2019 until the option was fully vested on May 10, 2023.
Options exercised 1,452 shares Employee stock options exercised into common stock on September 1, 2026
Option exercise price $1.86 per share Exercise price for employee stock options converted into common stock
Sale price $25.47 per share Price for sale of 1,452 shares of common stock on September 1, 2026
Shares sold 1,452 shares Common stock sold in a code “S” transaction on September 1, 2026
Options remaining after transaction 60,858 options Total employee stock options held directly after the reported exercise
Option expiration date August 28, 2029 Expiration date for the employee stock option involved in the exercise
Vesting schedule fraction 1/48 of total shares monthly Vesting pattern from June 10, 2019 until fully vested on May 10, 2023
Rule 10b5-1 trading plan regulatory
"This transaction was effected pursuant to a Rule 10b5-1 trading plan"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
Employee Stock Option financial
"security_title: Employee Stock Option (right to buy)"
An employee stock option is a promise that lets a worker buy company shares later at a predetermined price, often after they stay for a certain period or meet performance goals — think of it like a coupon that locks in today's price for a future purchase. It matters to investors because options align employees’ incentives with company performance, can increase the number of shares outstanding (dilution) when exercised, and represent a compensation cost that affects reported profits and shareholder value.
derivative security financial
"transaction_code_description: Exercise or conversion of derivative security"
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
beneficial ownership financial
"disclaims beneficial ownership except to the extent of any pecuniary intere"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

FAQ

What insider transactions did NRIX’s Chief Scientific Officer report on this Form 4?

The Chief Scientific Officer, Gwenn Hansen, exercised employee stock options for 1,452 shares of Nurix Therapeutics common stock at $1.86 per share and sold 1,452 shares of common stock at $25.47 per share on September 1, 2026.

Were the NRIX insider transactions made under a Rule 10b5-1 trading plan?

Yes. The filing states that the reported transactions were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person, indicating the trades were pre-arranged under that plan.

How many NRIX employee stock options did the insider exercise and at what price?

The insider exercised 1,452 employee stock options to acquire Nurix Therapeutics common stock at an exercise price of $1.86 per share. These options were fully vested as of May 10, 2023 according to the vesting footnote.

At what price were the NRIX shares sold in the reported insider sale?

The reported sale involved 1,452 shares of Nurix Therapeutics common stock at a price of $25.47 per share on September 1, 2026, classified as a sale transaction with code “S.”

How many NRIX stock options does the insider hold after these transactions?

After the option exercise, the reporting person held 60,858 employee stock options directly. These options relate to Nurix Therapeutics common stock and have an expiration date of August 28, 2029.

What is the vesting schedule disclosed for the exercised NRIX stock options?

The filing notes that the stock option vested as to 1/48 of the total shares monthly beginning June 10, 2019 until the option was fully vested on May 10, 2023.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Hansen Gwenn

(Last)(First)(Middle)
C/O NURIX THERAPEUTICS, INC.
1600 SIERRA POINT PKWY

(Street)
BRISBANE CALIFORNIA 94005

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Nurix Therapeutics, Inc. [ NRIX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Scientific Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
09/01/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock09/01/2026M(1)1,452A$1.86118,679D
Common Stock09/01/2026S(1)1,452D$25.47117,227D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Employee Stock Option (right to buy)$1.8609/01/2026M(1)1,452 (2)08/28/2029Common Stock1,452$060,858D
Explanation of Responses:
1. This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.
2. The stock option vested as to 1/48 of the total shares monthly beginning June 10, 2019 until the option was fully vested on May 10, 2023.
Remarks:
/s/ Daniel Burbach, as Attorney-in-Fact for Gwenn Hansen09/01/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)